Microfluidic Extraction Uses High-Density Microarray Biochips

Further investigation of the human genome by resequencing will especially benefit from the new method.

Febit (Heidelberg, Germany) announced the receipt of US patent #7320862 on its microfluidic microarray-based method for extraction of DNA and RNA. Febit uses its microfluidic biochip system Geniom for sequence-based selective isolation of nucleic acids from genomic samples. This new approach to high-throughput sequencing essentially relies on high-density microarray biochips with flexible design, a technology established by febit several years ago. The newly patented method is known as hybselect, targeted sequencing or sequence capture. Using this innovative technique, researchers are able to isolate genes or genomic regions of interest from a complex DNA sample before sequencing.

Febit microfluidic biochip systems have been effectively used for several years in DNA analysis and synthesis. The latest patent was granted in the United States; patents in Europe, and other foreign countries will soon follow. Febit currently holds more than 20 patents and patent applications. In addition to bioanalytics, the company's intellectual property range of products predominantly covers the production of synthetic genes on biochips. Using a focused application strategy, febit has been able to secure intellectual property rights on important product components, processes, and evolving technologies.

Febit's integration of DNA synthesis, analysis, and support in experiment design and bioinformatics helps to understand the data and convert it into results. Geniom is a technologic and service platform implemented in basic and applied research by well known institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes, providing superior time- and cost-efficiency combined with a wide spectrum of applications.


Related Links:
febit